CATALYSIS SL
🇪🇸Spain
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Phase 2
Completed
- Conditions
- Adenocarcinoma of the PancreasAdvanced CancerEndocrine Gland NeoplasmsDigestive System DiseasesEndocrine System DiseasesDigestive System NeoplasmsPancreatic CancerPancreatic DiseasesPancreatic Neoplasms
- Interventions
- Dietary Supplement: Ocoxin-Viusid®
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 30
- Registration Number
- NCT03717298
- Locations
- 🇨🇺
"Hermanos Ameijeiras" Surgical Clinical Hospital, La Habana, Cuba
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
Phase 2
Completed
- Conditions
- Esophageal Viral WartEsophageal Verrucous CarcinomaPapillomavirus InfectionsPapilloma Viral Infection
- Interventions
- Dietary Supplement: Viusid PlaceboDietary Supplement: Viusid®Dietary Supplement: Glizigen®Dietary Supplement: Glizigen Placebo
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 110
- Registration Number
- NCT03584308
- Locations
- 🇨🇺
Gastroenterology Institute, Vedado, La Habana, Cuba
Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot Ulcer
Phase 2
Completed
- Conditions
- Diabetic Foot UlcerDiabetic FootDiabetes Mellitus, Type 2
- Interventions
- Dietary Supplement: DIAMELDietary Supplement: Placebo
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 100
- Registration Number
- NCT03583593
- Locations
- 🇨🇺
National Institute of Endocrinology, Vedado, Havana, Cuba
Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.
Phase 2
Completed
- Conditions
- Mucositis Oral
- Interventions
- Dietary Supplement: Oncoxin®
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 15
- Registration Number
- NCT03577535
- Locations
- 🇷🇺
Medical Scientific centre of professor Shumsky, Samara, Samara Oblast, Russian Federation
Evaluation of Ocoxin®-Viusid® in Breast Cancer
Phase 2
Completed
- Conditions
- Breast CancerAdriamycin ToxicityBreast CarcinomaCyclosporine Toxicity
- Interventions
- Combination Product: CT + Ocoxin-ViusidCombination Product: CT + Placebo
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 120
- Registration Number
- NCT03576521
- Locations
- 🇨🇺
National Institute of Oncology and Radiobiology (INOR), La Habana, Cuba
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Phase 2
Completed
- Conditions
- CarcinomaEndocrine Gland NeoplasmUrogenital NeoplasmsFemale Urogenital DiseasesNeoplasms, Glandular and EpithelialAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital Diseases and Pregnancy ComplicationsOvarian NeoplasmGonadal Disorders
- Interventions
- Dietary Supplement: Ocoxin-Viusid
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 40
- Registration Number
- NCT03562897
- Locations
- 🇨🇺
National Institute of Oncology and Radiobiology (INOR), Havana, Cuba
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
Phase 2
Completed
- Conditions
- Rectal DiseasesColonic DiseasesColorectal NeoplasmIntestinal NeoplasmsDigestive System NeoplasmIntestinal DiseaseGastrointestinal NeoplasmsGastrointestinal DiseaseDigestive System Disease
- Interventions
- Dietary Supplement: Ocoxin-Viusid
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 40
- Registration Number
- NCT03559543
- Locations
- 🇨🇺
National Institute of Oncology and Radiobiology (INOR), Havana, Cuba
Oncoxin® and Quality of Life in Cancer Patients
Phase 4
Completed
- Conditions
- Non-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage IIIGastric Cancer Stage IIGastric Cancer Stage III
- Interventions
- Dietary Supplement: ONCOXIN®
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 133
- Registration Number
- NCT03550482
- Locations
- 🇰🇿
Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan
🇰🇿State Municipal Enterprise on the Right of Economic Management "Almaty Oncology Center" of Almaty Healthcare Administration, Almaty, Kazakhstan
🇷🇺State-funded Institution of Khanty-Mansiysk Regional Clinical Hospital, Ugra, Tyumen Region, Russian Federation
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Phase 2
Completed
- Conditions
- Esophageal NeoplasmsHead and Neck NeoplasmsDigestive System NeoplasmGastrointestinal DiseaseStomach DiseasesStomach NeoplasmGastrointestinal NeoplasmsEsophageal DiseasesDigestive System DiseaseEsophagogastric Junction Disorder
- Interventions
- Dietary Supplement: Ocoxin-Viusid®
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 45
- Registration Number
- NCT03549494
- Locations
- 🇨🇺
National Institute of Oncology and Radiobiology (INOR), Havana, La Habana, Cuba
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Phase 2
Recruiting
- Conditions
- Neoplasia; Intraepithelial, CervixGlandular NeoplasmsEpithelial NeoplasmNeoplasmsCarcinoma
- Interventions
- Dietary Supplement: Glizigen® + Ocoxin-Viusid®
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 62
- Registration Number
- NCT03549273
- Locations
- 🇨🇺
Our Lady of Rule No. 52 &/Remedios and Quiroga, Luyano, Havana, Cuba
© Copyright 2025. All Rights Reserved by MedPath